An Observational Study of Avastin (Bevacizumab) and Interferon Alpha 2a in Patients With Metastatic Renal Cell Cancer (VERA)

An Open Label, Prospective, Observational, Local, Non-interventional Study of BeVacizumab (Avastin) and IntErpherone (IFN) Alpha 2a in Patients With Metastatic and Locally Advanced Renal Cell CAncer (VERA Study)

This prospective observational study will evaluate the efficacy and safety of Avastin (bevacizumab) in combination with interferon alpha 2a in patients with previously untreated metastatic renal cell cancer. Data will be collected from each patient for up to 4 years.

Inclusion Criteria:

• Adult patients, >/= 18 years of age
• Histologically confirmed metastatic renal cell cancer, clear cell type
• Eligible for treatment with Avastin and interferon alpha 2a according to local prescribing information

Exclusion Criteria:

• Contraindications for Avastin or interferon alpha 2a treatment according to local Summary of Product Characteristics
• Known hypersensitivity to Avastin and/or interferon alpha 2a or any of its excipients